Hibercell, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.hibercell.com
Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06234605
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05484011
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
- Conditions
- Malignant Neoplasm of Breast
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05159778
- Locations
- 🇺🇸
The University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of Colorado at Denver, Denver, Colorado, United States
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
- Conditions
- Squamous Cell Carcinoma of Head and NeckOther Solid TumorsColo-rectal CancerNon Small Cell Lung CancerTransitional Cell Carcinoma of the BladderClear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05121948
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
- Conditions
- Pathologic Stage III Cutaneous Melanoma AJCC v8
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- HiberCell, Inc.
- Registration Number
- NCT04995094
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸Ichan School of Medicine at Mount Sinai, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- Next